Abstract # 1094 Cetuximab (C225) Plus Cisplatin (CDDP). Irinotecan (CPT11) And Thoracic Radiotherapy (TRT) Definitive Treatment For Locally Advanced, Clinically Unresectable Esophageal Cancer: A Southwest Oncology Group (SWOG) Phase II Trial With Molecular Correlates (S0414)

Presenter: Charles Thomas, MD

About the Presenter:
Dr. Thomas (Prof. & Chair, Dept. of Radiation Medicine @ the OHSU Knight Cancer Institute (www.ohsu.edu/radmedicine) is dedicated to providing the highest quality care available to his patients. Board-certified in radiation oncology, medical oncology, and internal medicine, he’s an active an member of the multidisciplinary programs in Thoracic and GI Oncology & the Solid Tumor (Program 3) research program within the OHSU Knight Cancer Institute. Dr. Thomas is the chair of the American College of Radiology’s Patterns-of-Care GI Comm & the Radiation Oncology Committee of the American College of Surgeons Oncology Group (www.acosog.org) and is very active in protocol development within the U.S. cooperative group mechanism, with a focus on novel therapeutic translational clinical research in thoracic and GI cancers. He’s on the editorial board of multiple journals and has edited multiple textbooks, including Esophageal Cancer: Principles & Practice (http://www.demosmedpub.com/prod.aspx?prod_id=9781933864174). Dr. Thomas has served as an examiner for the American Board of Radiology, and has served on multiple committees of the Am Soc of Clinical Oncology (www.asco.org), Am Society of Radiation Oncology (www.astro.org), Southwest Oncology Group (www.swog.org), Radiation Oncology Institute, Radiological Society of North American (www.rsna.org), Society of Chairs of Academic Radiation Oncology Programs (SCAROP), & the Radiation Therapy Oncology Group (www.rtog.org) Finally, Dr. Thomas is an active intramural and extramural mentor of high school, college, & medical students, as well as housestaff, fellows, and faculty.
Contact the presenter at: thomasch@ohsu.edu


E-mail a friend about this poster:
Enter email address: